Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05422911 · ClinicalTrials.gov registry record · Phase 2
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
NCT05422911: Recruiting Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
NCT05422911 is a Phase 2 study that is actively recruiting participants, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 192 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05422911, a Phase 2 study, is actively recruiting participants, sponsored by Sun Pharmaceutical Industries Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
Study Summary
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings should now be explored. In the egalitarian system that is the VHA the treatment of prostate cancer is excellent and uniform across the US. The choices made are clearly personalized, given not all men received all therapies and that younger Veterans were treated more aggressively. But with survivals that rival those in registration trials that enroll optimally fit individuals usually not encumbered by the co-morbidities that afflict many Veterans, the outcomes are testimony to the fact that for this common malady of older Veterans with whom VA physicians have broad experience the care administered is unsurpassed. Importantly this care at least as regards Veterans with mCRPC demonstrates that given equal access to health care, all men with prostate cancer fare comparably well. As our sophistication in categorizing cancers molecularly has increased this study will look to better examine any emerging differences across study participants.
Primary Outcome
Tumor growth rate (g)
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
- DRUG Abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT05422911 shows while recruiting
NCT05422911 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% higher).
The record links to 0 conditions, and to 3 interventions - of which Apalutamide is the first listed.
NCT05422911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05422911 about?
NCT05422911 is a clinical study titled "Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.". The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings s...
What is the current status of trial NCT05422911?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2022-08-31. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT05422911?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT05422911?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05422911's enrollment target sits among peer trials
192 352nd of 2000 higher than 1,648 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI